Connect
MJA
MJA

Nebulised frusemide for the symptomatic treatment of end-stage congestive heart failure

Kate A Towers, Kimberley A Bardsley and Peter S Macdonald
Med J Aust 2010; 193 (9): 555.
Published online: 1 November 2010

To the Editor: We report the use of nebulised frusemide for the symptomatic treatment of end-stage congestive heart failure (CHF). An 84-year-old man with New York Heart Association class IV CHF was referred to the Community Heart Failure Team at St Vincent’s Hospital, Sydney, for ongoing management after a hospital admission for acute pulmonary oedema. His medical history included aortic stenosis, pulmonary hypertension, type 2 diabetes, chronic renal failure, atrial fibrillation, hypertension, chronic obstructive pulmonary disease (COPD) and hypercholesterolaemia.

  • Kate A Towers
  • Kimberley A Bardsley
  • Peter S Macdonald

  • St Vincent’s Hospital, Sydney, NSW.


Acknowledgements: 

We thank Professor Patricia Davidson and Dr Phillip Newton of the Centre for Cardiovascular and Chronic Care, Curtin University, Sydney, NSW, for their assistance.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.